Stockreport

Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program

Lineage Cell Therapeutics, Inc.  (LCTX) 
PDF OPC1 Overall Safety Profile Excellent with Motor Recovery Gains in Upper Extremities Maintained Through Year 2 Follow-Ups Available to DateOPC1 Manufacturing Fully Trans [Read more]